For a syringe I believe that you can use the same type you use for insulin
The assessment of results was made at 24 and 96 hours after peptide administration and included changes in the kidneys on a scale from 0 to 3, where: 0 - healthy kidney, 1 - mild hydronephrosis, 2 - moderate hydronephrosis, visible dilation of the renal pelvis, few changes on the kidney surface, 3 - severe hydronephrosis, dilation of the renal pelvis, thinning of the renal parenchyma, and a significant number of changes on the kidney surface
Keep in mind that evidence is preliminary and largely based on animal studies or small human trials
For these reasons, we assume that clinicians who received reweighting in the CY 2023 performance period/2025 MIPS payment year are also approved for reweighting in the CY 2026 performance period/2028 MIPS payment year
Topical dosage was 0.4 g/eye to 0.4 ng/eye